¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tubular rejection fraction ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • simple tubular heart
    ´Ü¼ø´ë·Õ½ÉÀå, ´Ü¼ø°ü»ó½ÉÀå
  • attributable fraction
    ±â¿©ºÐÀ²
  • absorbed fraction
    Èí¼öºÐÀ²
  • ejection fraction
    ¹ÚÃâ·ü, ¹ÚÃâºÐÀ²
  • etiologic fraction
    ¿øÀκÐÀ²
  • filtration fraction
    ¿©°úºÐÀ², °Å¸£±âºÐÀ²
  • fraction
    1. ºÐ¼ö, ºÐÀ² 2. ºÎºÐ 3. ºÐȹ, ºÐÇÒ
  • fraction of inspired oxygen
    ÈíÀÔ»ê¼Ò³óµµ
  • growth fraction
    ¼ºÀåºÐÀ²
  • hypoxic fraction
    Àú»ê¼ÒºÐȹ
  • human plasma protein fraction
    »ç¶÷Ç÷Àå´Ü¹éºÐÀ²
  • inspired oxygen fraction
    µé¼û»ê¼ÒºÐÀ², Èí±â»ê¼ÒºÐÀ²
  • mole fraction
    ¸ôºÐÀ²
  • motor unit fraction
    ¿îµ¿´ÜÀ§ºÐȹ
  • oxygen fraction in inspired air
    ÈíÀÔ»ê¼Ò³óµµ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inspiratory expiratory ratio
    µé¼û³¯¼ûºñÀ², ÈíÈ£±â´ëºñ
  • odds ratio
    ±³Â÷ºñ
  • scatter-maximum ratio
    ÃÖ´ë»ê¶õºñ
  • segregation ratio
    ºÐ¸®ºñ
  • sex ratio
    ¼ººñ
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
  • uptake ratio
    ¼·ÃëÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • filtration fraction
    °Å¸£±âºÐÀ², ¿©°úºÐÀ²
  • growth fraction
    ¼ºÀåºÐÀ²
  • hypoxic fraction
    Àú»ê¼ÒºÐȹ
  • inspired oxygen fraction
    Èí±â»ê¼ÒºÐÀ²
  • mole fraction
    ¸ôºÐÀ²
  • motor unit fraction
    ¿îµ¿´ÜÀ§ºÐȹ
  • volume fraction
    ºÎÇǺÐÀ², ¿ëÀûºÐÀ²
  • renal tubular acidosis
    ÄáÆÏ´¢¼¼°ü»êÁõ
  • tubular adenoma
    ´ë·Õ»ùÁ¾
  • tubular bronchiectasis
    °ü¸ð¾ç±â°üÁöÈ®ÀåÁõ
  • maximal tubular excretory capacity
    ÃÖ´ë¿ä¼¼°ü¹è¼³·®
  • maximal tubular reabsorption capacity
    ÃÖ´ë¿ä¼¼°üÀçÈí¼ö·®
  • tubular carcinoma
    °ü¾ÏÁ¾
  • tubular diuresis
    ¿ä¼¼°üÀÌ´¢
  • tubular ectasia
    ¿ä¼¼°üÈ®Àå(Áõ)
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunological rejection
    ¸é¿ªÇÐÀû°ÅºÎ
  • rejection
    °ÅºÎ (ËÞÜú)
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection, allograft
    µ¿Á¾À̽Ä(Æí)°ÅºÎ(¹ÝÀÀ)
  • rejection, hypersensitivity to
    °ÅºÎ¿¡ ´ëÇÑ °ú¹Î(-¼º)
  • Filtration fraction
    ¿©°úºÐÀ²(¡­ÝÂëÒ)
  • Miettinen etiologic fraction
    ¹Ì¿¡Æ¼³Ùº´ÀκÐȹ
  • absorbed fraction
    Èí¼öºÐÀ²
  • fraction
    ºÐȹ(ÝÂüñ), ºÐÀ²(ÝÂëÒ).
  • fraction
    ºÐȹ
  • fraction size
    ºÐÇÒ¼±·®
  • growth fraction
    Áõ½ÄºÐȹ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection, allograft
    µ¿Á¾À̽Ä(Æí)°ÅºÎ(¹ÝÀÀ)
  • rejection, hypersensitivity to
    °ÅºÎ¿¡ ´ëÇÑ °ú¹Î(-¼º)
  • specimen rejection
    °Ëü°ÅÀý
  • transplant rejection
    À̽İźÎ(ì¹ãÕËÞÜú).
  • tumor associated rejection antigen
    Á¾¾ç°ü·Ã°ÅºÎÇ׿ø
  • absorbed fraction
    Èí¼öºÐÀ²
  • early labeled fraction
    Á¶±âÇ¥ÁöºÐȹ(¡­øöãÛÝÂüñ).
  • ejection fraction
    ¹ÚÃâ°è¼ö.
  • ejection fraction
    ¹ÚÃâÀ² (ÚÑõó×Ë)
  • ejection fraction
    ¹ÚÃâ°è¼ö(ÚÑõóÌõâ¦).
  • ejection fraction
    ±¸ÃâÀ²
  • etiologic fraction
    ¿øÀÎÀû ¿ä¼Ò
  • filtration fraction
    ¿©°úºÐÀ²
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pH 5 fraction
    pH 5 ºÐȹ(ÝÂüñ)
  • pre-beta fraction
    ÇÁ·¹º£Å¸ºÐȹ(ÝÂüñ)
  • saponifiable fraction
    °¡(ʦ)ºñ´©È­ ºÐȹ(ÝÂüñ)
  • saturation fraction
    Æ÷È­ ºÐȹ(øéûùÝÂüñ)
  • S-100 fraction
    S-100 ºÐȹ(ÝÂüñ)
  • soluble fraction
    °¡¿ë ºÐȹ(ʦéÁÝÂüñ)
  • subcellular fraction
    ¼¼Æ÷ÇÏ ºÐȹ(á¬øàù»ÝÂüñ)
  • volume fraction
    ¿ëÀû ºÐȹ(é»îÝÝÂüñ)
  • absorption ratio
    Èí¼öÀ² (ýåâ¥ëÒ)
  • acceptor-control ratio
    ¼ö¿ëü Á¦¾îÀ² (â¥é»ô÷ ð¤åÙëÒ)
  • affinity ratio
    ģȭºñ(öÑûúÝï)
  • A/G ratio
    A/G ºñ (Ýï)
  • albumin/globulin ratio
    ¾ËºÎ¹Î/±Û·ÎºÒ¸° ºñ(Ýï)
  • asymmetry ratio
    ºÒ±Õµîºñ (ÝÕгÔõÝï)
  • A+T/G+C ratio
    A+T/G+C ºñ (Ýï)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ratio
    ºñ
  • signal to noise ratio [=SNR]
    ½ÅÈ£´ëÀâÀ½ºñ
  • SNR [=signal to noise ratio]
    ½ÅÈ£´ëÀâÀ½ºñÀ²
  • uptake ratio
    ¼·ÃëÀ²
  • velocity ratio
    ¼Óµµºñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FF degree of fineness of abrasive particles; fat-free; father factor; fecal frequency; fertility factor...
L/S lactase/sucrase [ratio]; lecithin/ sphingomyelin [ratio]; lipid/saccharide [ratio]; longitudinal sec...
TARA total articular replacement arthroplasty; tumor-associated rejection antigen
A/G ratio Albumin/Globulin ratio; ¾ËºÎ¹Î´ë ±Û·ÎºÒ¸°ÀÇ ºñÀ²
S/D ratio Systolic / Diastolic ratio
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AVR Acute vascular rejection
CR Chronic rejection
DXR Delayed xenograft rejection
HAR Hyperacute rejection
AR allograft rejection
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • absorbed fraction
    Èí¼öºÐÀ²
  • ejection fraction
    ¹ÚÃâ °è¼ö
    ½É½Ç ÀÌ¿Ï ¸»±âÀÇ ½É½Ç Ç÷¾×·®¿¡ ´ëÇÑ 1ȸ ¹ÚÃâ·® ºñ¸¦ ¸»Çϸç, ¾ÈÁ¤½Ã ¾à 60%°¡ µÈ´Ù.
  • filtration fraction
    ¿©ÆÄºÐÀ²
  • fraction size
    ºÐÇÒ¼±·®
  • hypoxic fraction
    Àú»ê¼Ò ºÐȹ
  • liver isozyme fraction
    °£ È¿¼Ò À¯ºÐ
  • molar fraction
    ¸ôºÐÀ²
  • partial fraction
    ºÎºÐ ºÐ¼ö, ºÐȹ
  • serum cholesterol fraction
    Ç÷û ÄÝ·¹½ºÅ×·Ñ ºÐȹ
    Ç÷û Áß ÃÑÄÝ·¹½ºÅ×·ÑÀº Æò±Õ 200mg 100ml ¿¡½ºÅÍÈ­µÇÁö ¾ÊÀº À¯¸®ÇÑ ÄÝ·¹½ºÅ×·ÑÀº Æò±Õ 55mgÀÌ´Ù.
  • air entrainment ratio
    °ø±â À¯ÀÔ·ü
  • benefit/risk ratio
    À¯ÀÍ/À¯ÇØ ºñÀ²
  • body-weight ratio
    üÁß ½ÅÀå ºñ
  • cardiothoracic ratio
    ½ÉÈäºñ, ½ÉÈä°û ºñ, ½ÉÈä °è¼ö
  • cell color ratio
    Ç÷±¸»ö¼Òºñ, ÀûÇ÷±¸ »ö¼Òºñ
  • child woman ratio
    ¸ð¾Æ ºñÀ²
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
amorphous fraction of adrenal cortex Noncrystalline residue of an acetone extract of the adrenal cortex after crystalline steroids, e.g., corticosterone, deoxycorticosterone, etc., have been isolated.
(05 Mar 2000)
attributable fraction <epidemiology> The same as aetiological fraction.
(05 Dec 1998)
recombination fraction The proportion of progeny of a mating pair of specific genotype and coupling phase that are recombinant; there must be no differential selection among the possible types of progeny, and the recombination fraction should be the same regardless of the alleles involved or their coupling phase.
(05 Mar 2000)
regurgitant fraction The amount of blood regurgitated into a cardiac chamber divided by the stroke output; normally, no blood regurgitates; in patients with severe valvular lesions such as mitral or aortic insufficiency, regurgitation can approach 80%; this fraction affords a quantitative measure of the severity of the valvular lesion.
(05 Mar 2000)
microsomal fraction Artifactual vesicles formed from the endoplasmic reticulum when cells are disrupted. They are isolated by differential centrifugation and are composed of three structural features: rough vesicles, smooth vesicles, and ribosomes. Numerous enzyme activities are associated with the microsomal fraction. (glick, glossary of biochemistry and molecular biology, 1990; from rieger et al., glossary of genetics: classical and molecular, 5th ed)
(12 Dec 1998)
mole fraction The ratio of the moles of one component of a system to the total moles of all the components present.
(05 Mar 2000)
human antihemophilic fraction A lyophilised concentrate of factor VIII, obtained from fresh normal human plasma; used as a haemostatic agent in haemophilia.
Synonym: antihemophilic globulin, human antihemophilic fraction.
(05 Mar 2000)
human plasma protein fraction A sterile solution of selected proteins derived from the blood plasma of adult human donors, containing 4.5 to 5.5 g of protein per 100 ml, of which 83 to 90% is albumin and the remainder is alpha-and beta-globulins; used as a blood volume supporter.
(05 Mar 2000)
dried human plasma protein fraction Freeze-dried human plasma protein fraction.
(05 Mar 2000)
ejection fraction <cardiology> A measure of ventricular contractility, equal to normally 65
filtration fraction The fraction of the plasma entering the kidney that filters into the lumen of the renal tubules, determined by dividing the glomerular filtration rate by the renal plasma flow; normally, it is around 0.17.
(05 Mar 2000)
fraction In chemistry, one of the separable constituents of a substance.
(18 Nov 1997)
fraction collector A device used to collect the eluate from a column in column chromatography.
(05 Mar 2000)
fraction I protein <protein> See ribulose bisphosphate carboxylase/oxidase RUBISCO).
(18 Nov 1997)
acute tubular necrosis <nephrology> A kidney disorder that results in damage to the renal tubule cells leading to acute renal failure. Acute tubular necrosis can result from any condition which deprives the kidney of oxygen (ischaemia).
Acute tubular necrosis may occur as a complication of shock, trauma or sepsis. Conditions such as diabetes or liver disease can predispose people to the development of acute tubular necrosis. Certain medications (for example aminoglycosides, amphotericin B, cyclosporine) are known to cause acute tubular necrosis as a toxic side effect. Radiopaque contrast dyes, used in some radiologic procedures, may also result in acute tubular necrosis as a rare complication from contrast dye use.
Acronym: ATN
(13 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • improper fraction
    (¼ö)°¡ºÐ¼ö
  • packing fraction
    ºñÁú·® ÆíÂ÷
  • partial fraction
    ºÎºÐ ºÐ¼ö 
  • proper fraction
    ÁøºÐ¼ö
  • ratio
    ºñ
  • cash ratio
    (ÀºÇàÀÇ ÁöºÒ Áغñ±ÝÀÇ ÃÑ¿¹±Ý¿¡ ´ëÇÑ)Çö±Ý ºñÀ²
  • compression ratio
    (¿£ÁøÀÇ) ¾ÐÃàºñ
  • conversion ratio
    Àüȯ ºñÀ²(Çٺп­½Ã ÇϳªÀÇ ¿øÀÚ¿¡¼­ »ý±â´Â ¿øÀÚÀÇ ¼ö
  • cost performance (ratio)
    ºñ¿ë´ë ¼º´Éºñ
  • direct ratio
    (¼ö)Á¤ºñ;Á¤ºñ·Ê
  • elderly dependency ratio
    ³ë·ÉÀÚ(ÇÇ)ºÎ¾ç·ü
  • focal ratio
    =F-NUMBER
  • inverse ratio
    (¼ö)¹Ýºñ;¿ªºñ
  • mass ratio
    Áú·®ºñ (ÃßÁøºÎ¸¦ Á¦¿ÜÇÑ ·ÎÄÏ º»Ã¼¿¡ ´ëÇÑ ÃÑÁß·®ÀÇ ºñÀ²,ÃßÁø¾à ÃæÀüÀ²)
  • payout ratio
    ¹è´ç ¼ºÇâ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á